Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
This study has been completed.
Study NCT00001959 Information provided by National Institutes of Health Clinical Center (CC)
First Received: January 18, 2000 Last Updated: September 30, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fibrosis
Focal Glomerulosclerosis
Kidney Failure
Nephrotic Syndrome
Proteinuria
Additional conditions recognized in this trial
Glomerulosclerosis, Focal Segmental
Syndrome
More general conditions related to this trial
Disease
Glomerulonephritis
Kidney Diseases
Nephritis
Nephrosis
Pathologic Processes
Renal Insufficiency
Signs and Symptoms
Urination Disorders
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
Pirfenidone
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Back to top of Main Content
